Body Composition

Cagrilintide

Cagrilintide (Long-Acting Amylin Analog)

Amylin-pathway peptide studied alongside GLP-1 agonists

Research Status: Investigational; combination trials ongoing AM833
Mechanism of Action

How it works

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin. It engages amylin and calcitonin receptors to promote satiety and slow gastric emptying - a mechanism complementary to GLP-1 agonism.

Areas of Research

What the research explores

In published research, Cagrilintide has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Targets the amylin satiety pathway
  • Studied in combination with semaglutide (CagriSema)
  • Investigated for appetite regulation
  • Complementary mechanism to incretin agents
  • Active obesity-research candidate
Research Highlight

The combination of cagrilintide and semaglutide (CagriSema) has reported additive weight effects beyond either component alone in clinical studies.

Safety Profile

Adverse events & gaps

Investigational. Gastrointestinal effects reported; full profile still being characterized.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.